NO20091490L - Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer - Google Patents

Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer

Info

Publication number: NO20091490L
Authority: NO; Norway
Prior art keywords: leukemia; tyrosine kinase; abl tyrosine; cmin; bcr
Prior art date: 2006-09-22

Application number

NO20091490A

Other languages

English (en)

Norwegian (no)

Inventor

Insa Gathmann

Francois-Xavier Mahon

Mathieu Molimard

Stephane Picard

Yanfeng Wang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2009-04-16

Publication date

2009-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091490(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-16 Application filed by Novartis Ag filed Critical Novartis Ag

2009-06-15 Publication of NO20091490L publication Critical patent/NO20091490L/no

Links

208000032839 leukemia Diseases 0.000 title abstract 4
229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
229960002411 imatinib Drugs 0.000 abstract 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Pathology (AREA)
Ecology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Immunology (AREA)
Biophysics (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20091490A 2006-09-22 2009-04-16 Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer NO20091490L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82662206P	2006-09-22	2006-09-22
US82827806P	2006-10-05	2006-10-05
PCT/US2007/078978 WO2008036792A2 (fr)	2006-09-22	2007-09-20	Procédé d'optimisation de traitement de la leucémie philadelphie positive avec des inhibiteurs de tyrosine kinase abl

Publications (1)

Publication Number	Publication Date
NO20091490L true NO20091490L (no)	2009-06-15

Family

ID=39092883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091490A NO20091490L (no)	2006-09-22	2009-04-16	Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer

Country Status (24)

Country	Link
US (2)	US20090281113A1 (fr)
EP (2)	EP2251042A3 (fr)
JP (1)	JP5735742B2 (fr)
KR (1)	KR20090065512A (fr)
AT (1)	ATE495761T1 (fr)
AU (1)	AU2007299764B2 (fr)
BR (1)	BRPI0717099A2 (fr)
CA (1)	CA2662977A1 (fr)
CL (1)	CL2007002725A1 (fr)
CY (1)	CY1111356T1 (fr)
DE (1)	DE602007012122D1 (fr)
DK (1)	DK2068938T3 (fr)
HR (1)	HRP20110250T1 (fr)
IL (1)	IL197296A (fr)
MA (1)	MA30786B1 (fr)
MX (1)	MX2009003082A (fr)
NO (1)	NO20091490L (fr)
NZ (1)	NZ575113A (fr)
PL (1)	PL2068938T3 (fr)
PT (1)	PT2068938E (fr)
TN (1)	TN2009000094A1 (fr)
TW (1)	TWI398251B (fr)
WO (1)	WO2008036792A2 (fr)
ZA (1)	ZA200901220B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2237783T3 (pl) *	2008-01-23	2015-04-30	Novartis Ag	Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu
US8697702B2 (en)	2008-12-01	2014-04-15	Novartis Ag	Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
US20110046919A1 (en) *	2009-03-02	2011-02-24	Juliesta Elaine Sylvester	Method for accurate measurement of enzyme activities
FR2943418A1 (fr) *	2009-03-17	2010-09-24	Centre Nat Rech Scient	Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
EP3072964A1 (fr) *	2013-11-22	2016-09-28	National Center For Child Health And Development	Nouveau gène chimère atf7ip-pdgfrb pour la leucémie lymphoblastique aiguë
US9683220B2 (en)	2015-07-07	2017-06-20	Codexis, Inc.	P450-BM3 variants with improved activity
IT201900008808A1 (it)	2019-06-13	2020-12-13	Univ Ca Foscari	Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) *	2022-06-28	2022-09-02	北京赛诺浦生物技术有限公司	一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1169038B9 (fr)	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Inhibiteurs cycliques de proteine tyrosine kinase
GB0202873D0 (en)	2002-02-07	2002-03-27	Novartis Ag	Organic compounds
JP2005522221A (ja) *	2002-04-17	2005-07-28	ノバルティスアクチエンゲゼルシャフト	チロシンキナーゼ阻害剤に対する患者応答性の予測方法
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en)	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
RU2401265C2 (ru)	2004-06-10	2010-10-10	Айрм Ллк	Соединения и композиции в качестве ингибиторов протеинкиназы
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
MY148074A (en)	2005-05-10	2013-02-28	Novartis Ag	Pharmaceutical compositions comprising imatinib and a release retardant

2007
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 EP EP10171365A patent/EP2251042A3/fr not_active Withdrawn
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 CA CA002662977A patent/CA2662977A1/fr not_active Abandoned
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 EP EP07842842A patent/EP2068938B1/fr not_active Not-in-force
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 HR HR20110250T patent/HRP20110250T1/hr unknown
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/fr not_active Ceased
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TN2009000094A1 (en)	2010-08-19
HK1133194A1 (en)	2010-03-19
EP2251042A3 (fr)	2012-05-02
PL2068938T3 (pl)	2011-06-30
CY1111356T1 (el)	2015-08-05
US20170007605A1 (en)	2017-01-12
TWI398251B (zh)	2013-06-11
CA2662977A1 (fr)	2008-03-27
DK2068938T3 (da)	2011-04-04
IL197296A (en)	2011-11-30
NZ575113A (en)	2012-03-30
WO2008036792A2 (fr)	2008-03-27
HRP20110250T1 (hr)	2011-05-31
EP2068938B1 (fr)	2011-01-19
CL2007002725A1 (es)	2008-05-16
EP2251042A2 (fr)	2010-11-17
WO2008036792A3 (fr)	2008-11-13
KR20090065512A (ko)	2009-06-22
BRPI0717099A2 (pt)	2013-10-15
AU2007299764A1 (en)	2008-03-27
TW200822926A (en)	2008-06-01
US20090281113A1 (en)	2009-11-12
PT2068938E (pt)	2011-03-23
EP2068938A2 (fr)	2009-06-17
MX2009003082A (es)	2009-04-01
DE602007012122D1 (de)	2011-03-03
MA30786B1 (fr)	2009-10-01
JP5735742B2 (ja)	2015-06-17
IL197296A0 (en)	2011-08-01
ZA200901220B (en)	2010-02-24
RU2009114856A (ru)	2010-10-27
AU2007299764B2 (en)	2011-10-13
JP2010504353A (ja)	2010-02-12
ATE495761T1 (de)	2011-02-15

Similar Documents

Publication	Publication Date	Title
NO20091490L (no)	2009-06-15	Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer
Cappuzzo et al.	2003	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
EA201190042A1 (ru)	2012-02-28	Имидазопиразиновые ингибиторы тирозинкиназы syk
HUP0302332A2 (hu)	2003-10-28	Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
KR20050037510A (ko)	2005-04-22	키나제 억제제를 사용하는 암 치료 방법
BRPI0508286A (pt)	2007-07-31	métodos para determinar a possibilidade de efetividade de um tratamento seletivo de receptor de fator de crescimento epidérmico em um paciente, para tratar um paciente e para selecionar um composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, sonda, kit, composto que inibe a atividade catalìtica de cinase de um receptor de fator de crescimento epidérmico variante, composição farmacêutica, ácido nucléico e proteìna isolada
DK2413142T3 (da)	2013-07-22	Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor
Hoyt et al.	2016	Sleep quality and depressive symptoms after prostate cancer: The mechanistic role of cortisol.
KR20210137045A (ko)	2021-11-17	수면 개선 방법
EP1720574A4 (fr)	2009-09-09	Methode de traitement d'une croissance cellulaire anormale au moyen d'inhibiteurs c-met et m-tor
EA201071422A1 (ru)	2011-08-30	Способы лечения заболеваний, связанных с мейотическим кинезином
RU2020134183A (ru)	2020-12-01	Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
WO2010066891A3 (fr)	2010-08-26	Méthode de prédiction de la réponse à un traitement à l'aide d'inhibiteurs de tyrosine kinase ciblant la protéine de fusion bcr-abl chez des patients atteints de leucémie myéloïde chronique
DE602005008639D1 (de)	2008-09-11	Behandlung von entzündungen
RU2010101634A (ru)	2011-07-27	Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi
DK2196199T3 (da)	2014-11-03	Behandling af fantomfænomener
EA201300410A1 (ru)	2014-01-30	Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
TW200507828A (en)	2005-03-01	Method for treatment of chemotherapy-induced diarrhea
Aalykke et al.	2015	Participants and Non-participants in the Scand-Ankle study-An alcohol cessation intervention at the time of fracture surgery
Büchner et al.	2004	Two years of experience using stimulation rates between 800 and 5000 pps with the clarion CII implant
RU2483732C2 (ru)	2013-06-10	СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ
Radich	2023	The (near) miracle of therapy in chronic myeloid leukaemia.
EP2370078A1 (fr)	2011-10-05	Méthode d optimisation du traitement de la leucémie philadelphie positive avec du mésylate d imatinib
WO2001045690A3 (fr)	2002-07-25	Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes
ATE312612T1 (de)	2005-12-15	Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen

Legal Events

Date	Code	Title	Description
2015-04-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application